A synthetic peptide for use as a blocking control in assays to test for specificity of MAP2 K2 antibody, Alternative Names: MAP2K2 control peptide, MAP2K2 antibody Blocking Peptide, Anti-MAP2K2 Blocking Peptide, Mitogen-Activated Protein Kinase 2 Blocking Peptide, MAPKK2 Blocking Peptide, MEK2 Blocking Peptide, MKK2 Blocking Peptide, PRKMK2 Blocking Peptide, MAP2, MAP-2, MAP 2, MAP-2 Blocking Peptide, MAP 2 Blocking Peptide
MAP2K2 is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in MAP2K2 gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene.